• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Individualized approaches to thromboprophylaxis in atrial fibrillation
Publication date: March 2016 Source:American Heart Journal, Volume 173 Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in persons older than 55 years is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart rate control, and heart rhythm control comprise the 3 main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism, and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antagonist such as ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial
Conclusions Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD. Although these findings may reflect unmeasured clinical factors, further investigation is warranted to determine optimal aspirin use in patients with AF.
Source: American Heart Journal - July 9, 2016 Category: Cardiology Source Type: research

Risk of Major Cardiovascular and Neurologic Events with Obstructive Sleep Apnea among Patients with Atrial Fibrillation
ConclusionAmong patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.Graphical Abstract
Source: American Heart Journal - January 7, 2020 Category: Cardiology Source Type: research

Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease
Background: The impact of nonpersistence on events and of events on persistence is unclear. We studied the effects of nonpersistence on outcomes and events on nonadherence in a randomized placebo controlled trial in 40 countries on 25,620 patients.Methods: In the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), persistent patients (n = 20,991) were compared with individuals who had permanently stopped study medications (n = 4,629).Results: Older age, female gender, less physical activity, less education, and history of stroke/transient ischemic attack, depression, and diabetes we...
Source: American Heart Journal - June 26, 2013 Category: Cardiology Authors: Michael Böhm, Helmut Schumacher, Ulrich Laufs, Peter Sleight, Roland Schmieder, Thomas Unger, Koon Teo, Salim Yusuf Tags: Acute Ischemic Heart Disease Source Type: research

Individual Components of the Romhilt-Estes Left Ventricular Hypertrophy Score Differ in Their Prediction of Cardiovascular Events: the Atherosclerosis Risk in Communities (ARIC) Study
Conclusions The R-E score is predictive of CVD outcomes. The six R-E score components differ in their associations with different CVD outcomes, indicating that they may be electrical biomarkers of different physiological events within the myocardium. Graphical abstract
Source: American Heart Journal - October 4, 2015 Category: Cardiology Source Type: research

Prediction of Postoperative Cardiac Surgery Outcomes With a Novel Score: R2CHADS2
Conclusion The R2CHADS2 score estimates postoperative events with acceptable accuracy and if validated can be used as a simple preoperative drisk tool calculator.
Source: American Heart Journal - April 29, 2016 Category: Cardiology Source Type: research

Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2
Conclusion The R2CHADS2 score estimates postoperative events with acceptable accuracy and if further validated may be used as a simple preoperative risk tool calculator.
Source: American Heart Journal - May 30, 2016 Category: Cardiology Source Type: research

Cardiorespiratory Fitness and Non-fatal Cardiovascular events: A Population based Follow-up Study
Conclusion In this Finnish population, there is a strong, inverse, and independent association between CRF and acute non-fatal MI and HF risk.
Source: American Heart Journal - November 2, 2016 Category: Cardiology Source Type: research

Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study
Conclusion In this Finnish population, there is a strong, inverse, and independent association between CRF and acute nonfatal MI and HF risk.
Source: American Heart Journal - November 21, 2016 Category: Cardiology Source Type: research

Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
Publication date: Available online 7 March 2018 Source:American Heart Journal Author(s): Douglas L. Packer, Daniel B. Mark, Richard A Robb, Kristi Monahan, Tristram Bahnson, Kathleen Moretz, Jeanne Poole, Alice Mascette, Yves Rosenberg, Neal Jeffries, Hussein R. Al-Khalidi, Kerry L. Lee The Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA, NCT00911508)(1) trial is testing the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art pharmacologic therapy. This inte...
Source: American Heart Journal - March 8, 2018 Category: Cardiology Source Type: research

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research

Burden, timing, and relationship of cardiovascular hospitalization to mortality among Medicare beneficiaries with newly diagnosed atrial fibrillation
Conclusions: Cardiovascular hospitalization is common in the first year after AF diagnosis. Atrial fibrillation, heart failure, myocardial infarction, and stroke/transient ischemic attack account for half of primary hospitalization diagnosis. Cardiovascular hospitalization is independently associated with mortality, irrespective of time from diagnosis to first hospitalization, and represents a critical inflection point in survival trajectory. These findings highlight the importance of CV hospitalization as a marker of disease progression and poor outcomes. Efforts to clarify the determinants of hospitalization could inform...
Source: American Heart Journal - August 12, 2013 Category: Cardiology Authors: Mintu P. Turakhia, Matthew D. Solomon, Mehul Jhaveri, Pamela Davis, Michael R. Eber, Ryan Conrad, Nicholas Summers, Darius Lakdawalla Tags: Electrophysiology Source Type: research

Patients’ Time in Therapeutic Range on Warfarin Among U.S. Atrial Fibrillation Patients: Results from ORBIT-AF Registry
Conclusions Among AF patients in US clinical practices, TTR on warfarin is suboptimal and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research

Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality
Conclusions Large increases or sustained elevations in hs-CRP over a six-year period were associated with a subsequent increased risk of diabetes; and persons with sustained elevations in hs-CRP were at the highest risk of CVD and mortality. Two measurements of hs-CRP are better than one for characterizing risk and large increases are particularly prognostic.
Source: American Heart Journal - April 22, 2015 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5  6  7  8